How many years should Enasidenib be used continuously?

Enasidenib is a targeted drug used to treat IDH2 mutated relapsed or refractory acute myeloid leukemia (AML) by inhibiting mutations. IDH2enzyme activity, thereby reducing 2-hydroxyglutarate (2-HG) levels and restoring normal differentiation of leukemia cells. In clinical use, ensidipine is designed as a long-term oral treatment, but whether it can be used for a long time still needs to be evaluated based on the patient's individual situation.

Some clinical studies and real-world medication data have shown that the use of ensidipine can last for several years, and some patients have continued to take it for more than 2 years and are still effective and well tolerated. However, this does not mean that all patients are suitable to take the medication indefinitely. Usually, it can be continued as long as the patient benefits from it and does not experience serious adverse reactions or disease progression. In some clinical literature reports, there are also cases in which the drug has been used for more than 3 years or even longer.

It should be noted that during long-term use, doctors will regularly monitor the patient's blood routine, liver function, IDH2 mutation status, and bone marrow response to evaluate efficacy and safety. If the drug effect weakens or side effects increase, such as hyperuricemia, differentiation syndrome, etc., it may be necessary to adjust the dose, temporarily discontinue the drug, or change the treatment plan.

In summary, ensidipine can be used continuously for many years without progression or serious side effects, and some patients even take it continuously for more than 3 to 5 years. However, the treatment period must be strictly carried out under the guidance of a hematologist, and the course of treatment cannot be extended or stopped by oneself to ensure that the safety of medication is ensured while controlling the disease.

Reference materials:https://www.idhifa.com/